Literature DB >> 26507869

Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.

Jia-Jia Ding1, Guan Wang2, Wen-Xin Shi1, Hong-Hui Zhou1, En-Feng Zhao3.   

Abstract

OBJECTIVE: To assess the 5' CpG island methylation of Fanconi anemia, complementation group F (FANCF) gene in epithelial ovarian cancer (EOC) tissues and normal ovarian tissues and to investigate the relationship between FANCF methylation and clinicopathologic features and prognosis of EOC.
METHODS: The experiment was performed with 112 EOC tissue samples (case group) and 60 normal ovarian tissues (control group). With methylation-specific polymerase chain reaction (MSP), FANCF methylation status of cases and controls was assessed. And the association between FANCF methylation and the clinicopathological features of EOC was investigated with univariate survival analysis and Cox regression model analysis.
RESULTS: The methylation-positive rate of the case group was significantly higher than that of the control group (P = 0.015). The FANCF promoter methylation rates showed significant differences in the comparisons stratified by age, International Federation of Gynecology and Obstetrics (FIGO) staging, histopathological classification, and lymph node metastasis (all P < .05). Univariate survival analysis showed there were significant differences in mean survival time between the groups based on FIGO staging, histopathological classification, lymph node metastasis, and FANCF methylation (all P < .05). Cox regression model analysis suggested that FIGO staging and FANCF methylation were independent risk factors for EOC prognosis.
CONCLUSION: CpG island methylation of FANCF gene promoter region is strongly associated with the susceptibility and clinicopathologic features of EOC. The FIGO staging and FANCF methylation are independent risk factors for EOC prognosis.
© The Author(s) 2015.

Entities:  

Keywords:  FANCF; MSP; clinicopathologic features; epithelial ovarian cancer; methylation; prognosis; survival analysis; treatment

Mesh:

Substances:

Year:  2015        PMID: 26507869     DOI: 10.1177/1933719115612136

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  4 in total

1.  FANCF hypomethylation is associated with colorectal cancer in Han Chinese.

Authors:  Hang Yu; Ranran Pan; Tong Gao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  Turk J Gastroenterol       Date:  2020-08       Impact factor: 1.852

Review 2.  Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.

Authors:  Susana Romero-Garcia; Heriberto Prado-Garcia; Angeles Carlos-Reyes
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 5.738

Review 3.  Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.

Authors:  Negesse Mekonnen; Hobin Yang; Young Kee Shin
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  TET1 inhibits cell proliferation by inducing RASSF5 expression.

Authors:  Bo-Tai Li; Chao Yu; Ying Xu; Sheng-Bing Liu; Heng-Yu Fan; Wei-Wei Pan
Journal:  Oncotarget       Date:  2017-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.